



David M. Harris, Ph.D. (far left), Director, Science and Regulatory Affairs, PathoLase, Inc., conducts a training session at NYCPM. Michael J. Trepal, DPM, NYCPM VP for Academic Affairs & Dean, is shown using the laser as faculty members Simon M. Nzuzi, DPM (left, in dark suit) and Donna M. Alfieri, DPM, watch intently.

NEW YORK COLLEGE OF PODIATRIC MEDICINE RECEIVES DONATION OF PATHOLASE, INC.'S NEW PINPOINTE™ FOOTLASER™ AND WILL TEACH ITS USE IN CONJUNCTION WITH CLINICAL RESEARCH STUDY EVALUATING IT FOR TREATMENT OF TOENAIL FUNGUS

New York, NY, June 16, 2009 – The New York College of Podiatric Medicine (NYCPM), the nation's first and largest college of podiatric medicine, today announced that it has received a donation from PathoLase, Inc., of the company's patented new PinPointe™ FootLaser™ for the treatment of nail fungus (Onychomycosis), and will be teaching the College's students to use the new technology in conjunction with a clinical research study to be conducted at the College's clinical affiliate, Foot Clinics of New York.

The PinPointe FootLaser, which was recently featured on Good Morning America, uses a patented technology to treat toenail fungus (onychomycosis), an infection that affects an estimated two to thirteen percent of the U.S. population. PinPointe's laser light passes through the toenail without causing damage to the nail or surrounding skin. The procedure allows the new nail to grow in healthy and clear.

According to Dr. Michael Trepal, NYCPM Vice President for Academic Affairs and Dean, "We are very pleased to have the PinPointe FootLaser at the College to educate our students and faculty on an alternative method for treating the difficult and debilitating condition known as onychomycosis. We are also pleased that, as part of the clinical education we offer, and as part of the upcoming clinical trial, we will soon be able to offer patients at our clinical affiliate, Foot Clinics of New York, this alternative, non-invasive approach for patients suffering from toenail fungus."

Foot Clinics of New York expects that it will be able to start offering treatment with the PinPointe FootLaser beginning in late June.

About NYCPM

The New York College of Podiatric Medicine, established in 1911, is the first and largest of the nine U.S. schools of podiatric medicine. Its clinical affiliate—Foot Clinics of New York—is the world's largest foot health center, recording over 25,000 patient visits each year. NYCPM has graduated more than twenty-five percent of all practicing podiatrists in the nation, and is at the forefront of podiatric care in terms of education, public awareness, government legislation and professional advancement.

About PathoLase, Inc.

Founded in 2004, PathoLase, Inc. is a privately-held, emerging medical technology company with headquarters in Chico, California. PathoLase has assembled a world-class group of top scientists, academic thought leaders, and leading practitioners from around the world, to bring to market a new generation of laser technology solutions to address a series of medical issues from toenail fungus and periodontal disease to more serious life threatening problems, such as blood borne and respiratory infections. For more information, please visit www.pinpointefootlaser.com

Press Contact:

New York College of Podiatric Medicine, Foot Clinics of New York
Roger Greene
(212) 410-8147
rgreene@nycpm.edu